In-depth coverage of the UK’s exit from the EU, and what it means to pharma and healthcare.
ABPI says Norgine’s support will be important during Brexit.
Britain will be in “second or third tier” of drug launches, experts warn.
But longer-term benefits could include faster reimbursement decisions.
AstraZeneca chief considers two possible scenarios for post-Brexit regulation
Other Japanese firms could scale back UK investment.
Britain could be in “second rank” of medicines access, warn MPs.
European regulators concerned over impact of EMA move.
Make NHS best place to research and launch drugs, says ABPI.
May sets out plans to leave single market, and aim for EU free trade deal